PTC Therapeutics Inc
NASDAQ:PTCT

Watchlist Manager
PTC Therapeutics Inc Logo
PTC Therapeutics Inc
NASDAQ:PTCT
Watchlist
Price: 44.05 USD 0.25% Market Closed
Market Cap: 3.4B USD

PTC Therapeutics Inc
Investor Relations

Nestled in the heart of the biotechnology sector, PTC Therapeutics Inc. has carved a distinctive niche by foregrounding innovative genetic approaches to combat rare diseases. Founded in 1998, the company harnesses the power of science and technology to address unmet medical needs, focusing primarily on disorders originating from genetic mutations that disrupt cellular systems. At its core, PTC leverages its expertise in the discovery and development of small molecule drugs and gene therapies, an endeavor propelled by its proprietary technology platforms such as SmRT (suppressor of nonsense mutations readthrough) and dystrophin restoration technologies. These platforms enable PTC to target and modify specific gene expressions, offering potential treatments for conditions such as Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA), which have historically eluded effective therapies.

The company’s revenue generation pivots on two key streams: product sales and strategic collaborations. By marketing its FDA-approved therapies like Translarna and Emflaza for rare genetic disorders, PTC secures a steady flow of income that underscores its sustainable business model. Additionally, PTC forms strategic alliances and collaborative agreements with pharmaceutical giants, fostering a vibrant environment of shared knowledge and resources. These partnerships not only bolster its research and development capabilities but also offer potential milestone payments and royalties, further strengthening its financial portfolio. In this symbiotic landscape, PTC Therapeutics continues to navigate the complexities of biotech development, striving to transform the challenges of rare diseases into treatment opportunities, thereby weaving innovation into the very fabric of business efficacy.

Show more
Loading

Earnings Calls

2024 Q3
Nov 7, 2024
Show Transcript
Previous
Next
Strong Q3 performance boosts PTC's 2024 revenue outlook and future drug approvals.
2024 Q3
Nov 7, 2024

In the third quarter, PTC Therapeutics reported total revenue of $197 million, with significant contributions from its DMD franchise, particularly $52 million from Emflaza. Due to this strong performance, the company increased its 2024 revenue guidance to between $750 million and $800 million. PTC has submitted two NDAs to the FDA, expecting decisions in 2025, and plans to launch sepiapterin, aiming for a $1 billion opportunity in the U.S. alone. Their pipeline also includes promising treatments for Huntington's disease and ALS, reflecting PTC's strategic focus on rare diseases and unmet medical needs.

Show Full Analysis

Management

Dr. Stuart W. Peltz Ph.D.
Co-Founder, Senior Consultant & Member of Scientific Advisory Board
No Bio Available
Dr. Allan Steven Jacobson Ph.D.
Co-Founder, Chairman of Scientific Advisory Board & Independent Director
No Bio Available
Mr. Pierre Gravier M.S.
Chief Financial Officer
No Bio Available
Mr. Mark Elliott Boulding J.D.
Executive VP & Chief Legal Officer
No Bio Available
Mr. Eric Pauwels
Chief Business Officer
No Bio Available
Dr. Lee Golden M.D., Ph.D.
Executive VP & Chief Medical Officer
No Bio Available
Dr. Neil Almstead Ph.D.
Chief Technical Operations Officer
No Bio Available
Ms. Linda Montella Carter
Senior VP & Chief Information Officer
No Bio Available
Mr. Alex Kane
Investor Relations Officer
No Bio Available
Ms. Jane Baj
Vice President of Corporate Communications
No Bio Available

Contacts

Address
NEW JERSEY
South Plainfield
100 Corporate Ct
Contacts
+19082227000.0
www.ptcbio.com